[go: up one dir, main page]

WO2012165815A3 - 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 - Google Patents

종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 Download PDF

Info

Publication number
WO2012165815A3
WO2012165815A3 PCT/KR2012/004162 KR2012004162W WO2012165815A3 WO 2012165815 A3 WO2012165815 A3 WO 2012165815A3 KR 2012004162 W KR2012004162 W KR 2012004162W WO 2012165815 A3 WO2012165815 A3 WO 2012165815A3
Authority
WO
WIPO (PCT)
Prior art keywords
nano
tumor tissue
vehicle
cancer vaccine
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/004162
Other languages
English (en)
French (fr)
Other versions
WO2012165815A2 (ko
Inventor
고용성
김윤근
이은영
장수철
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POSTECH Academy Industry Foundation
Original Assignee
POSTECH Academy Industry Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POSTECH Academy Industry Foundation filed Critical POSTECH Academy Industry Foundation
Priority to CN2012800037132A priority Critical patent/CN103221034A/zh
Priority to JP2013534840A priority patent/JP2013543519A/ja
Priority to EP12793342.2A priority patent/EP2617413A4/en
Priority to US13/823,315 priority patent/US9220763B2/en
Publication of WO2012165815A2 publication Critical patent/WO2012165815A2/ko
Publication of WO2012165815A3 publication Critical patent/WO2012165815A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 암 백신에 관한 것으로, 구체적으로 종양 조직에서 유래한 나노소포체를 포함하는 암 치료용 약학적 조성물 및 상기 종양 조직 유래 나노 소포체를 이용하여 암을 치료하는 방법 등에 관한 것이다. 본 발명에 따른 종양 조직 유래 나노소포체 항원은 세포밖 소포체와 유사한 속성을 지니면서도 높은 수득률을 나타내고, 아울러 다양한 변형이 가능함으로써 암 치료백신 개발에 매우 유용할 것으로 기대된다.
PCT/KR2012/004162 2011-05-27 2012-05-25 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 Ceased WO2012165815A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2012800037132A CN103221034A (zh) 2011-05-27 2012-05-25 来自肿瘤组织的纳米囊泡及使用该纳米囊泡的癌症疫苗
JP2013534840A JP2013543519A (ja) 2011-05-27 2012-05-25 腫瘍組織に由来するナノベシクル、及びこれを用いた癌ワクチン
EP12793342.2A EP2617413A4 (en) 2011-05-27 2012-05-25 NANIUM DERIVED FROM A TUMOR TISSUE AND CANCER VACCINE THEREFOR
US13/823,315 US9220763B2 (en) 2011-05-27 2012-05-25 Nano-vehicle derived from tumor tissue, and cancer vaccine using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110050854A KR20120132183A (ko) 2011-05-27 2011-05-27 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
KR10-2011-0050854 2011-05-27

Publications (2)

Publication Number Publication Date
WO2012165815A2 WO2012165815A2 (ko) 2012-12-06
WO2012165815A3 true WO2012165815A3 (ko) 2013-02-07

Family

ID=47260042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004162 Ceased WO2012165815A2 (ko) 2011-05-27 2012-05-25 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신

Country Status (6)

Country Link
US (1) US9220763B2 (ko)
EP (1) EP2617413A4 (ko)
JP (1) JP2013543519A (ko)
KR (1) KR20120132183A (ko)
CN (1) CN103221034A (ko)
WO (1) WO2012165815A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6286445B2 (ja) * 2012-12-24 2018-02-28 セル・アイディアズ・ピーティーワイ・リミテッド がんの治療のためのワクチン及びワクチン有効性を増強するための組成物
KR101473557B1 (ko) 2013-03-29 2014-12-24 포항공과대학교 산학협력단 원심력을 이용한 세포유래 인공 마이크로베시클 제조 장치
KR101745455B1 (ko) * 2015-03-24 2017-06-09 포항공과대학교 산학협력단 수용액 이상계를 이용한 세포 밖 소포체의 다단계 정제방법
KR101761680B1 (ko) * 2015-03-31 2017-08-23 포항공과대학교 산학협력단 수용액 이상계를 이용한 세포 밖 소포체의 분리방법
KR101833502B1 (ko) * 2016-12-16 2018-03-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 위암 진단방법
CN108295250B (zh) * 2017-01-12 2023-07-21 湖北盛齐安生物科技股份有限公司 一种口服肿瘤疫苗及其用途
GB2574785A (en) 2017-09-15 2019-12-25 Jan Loetvall Method and system for identifying membrane proteins on extracellular vesicles
CN108324958B (zh) * 2018-05-17 2021-09-24 陕西师范大学 一种紫红素18-脂质体纳米囊泡的制备方法以及在制备用于治疗肿瘤药物中的应用
EP3908262A4 (en) 2019-01-09 2022-12-28 Exocure Biosciences, Inc. Bacteria-derived vesicles and uses thereof
CN110628719B (zh) * 2019-09-23 2021-08-24 山东省医学科学院基础医学研究所 一种诱导细胞快速产生囊泡的方法及其应用
CN110974976A (zh) * 2019-12-16 2020-04-10 天津市第三中心医院 羧甲基壳聚糖修饰载药囊泡及其制备与应用
CN111991565A (zh) * 2019-12-17 2020-11-27 河南牧业经济学院 促吞噬肽修饰阿魏酸生物可降解纳米囊泡的制备方法
CN113332312B (zh) * 2021-02-01 2023-02-24 浙江大学医学院附属邵逸夫医院 一种基于物理整粒的自成形血小板纳米囊泡及其制备方法
WO2022245144A1 (ko) * 2021-05-20 2022-11-24 주식회사 뉴메이스 고압 유체 분산 방법을 이용한 세포 유래 나노소포체의 제조 방법
KR20240085848A (ko) 2022-12-08 2024-06-17 서울대학교산학협력단 자연 살해 t 세포 리간드가 적재된 세포외 나노 소포체를 포함하는 혈액암에 대한 자가 항암 백신
CN116004538A (zh) * 2022-12-29 2023-04-25 华中科技大学 一种搭载细胞内生成dsRNA的纳米囊泡、制备与应用
CN118045086A (zh) * 2024-01-17 2024-05-17 中国科学院武汉病毒研究所 一种微酸响应型仿生纳米囊泡及其制备方法与应用
CN118059219B (zh) * 2024-04-19 2024-06-25 西南交通大学 一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075315A1 (en) * 2004-06-02 2010-03-25 Zbigniew Pietrzkowski Microvesicle-Based Compositions and Methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
CA2331115A1 (en) * 1998-05-11 1999-11-18 Inserm (Institut De La Sante Et De La Recherche Medicale) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
JP2003535017A (ja) * 1998-06-29 2003-11-25 ネクター セラピューティクス 微粒子デリバリーシステムおよび使用の方法
JP2005281266A (ja) * 2004-03-31 2005-10-13 Takeshi Kobayashi 温熱細胞ワクチンとサイトカインを含む医薬用組成物およびその調製方法
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
CA2648099C (en) * 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
DE102008033175A1 (de) * 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
CN102281867A (zh) * 2008-10-21 2011-12-14 杜门蒂斯有限公司 用于靶向树突细胞的组合物
EP3311833A3 (en) * 2009-08-26 2018-07-25 Selecta Biosciences, Inc. Compositions that induce t cell help
CN103002879B (zh) * 2010-07-01 2016-04-20 阿昂梅迪克斯公司 来自细胞原生质体的微泡及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075315A1 (en) * 2004-06-02 2010-03-25 Zbigniew Pietrzkowski Microvesicle-Based Compositions and Methods

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
K. AL-NEDAWI ET AL.: "Microvescicles: Messengers and mediators of tumor progression", CELL CYCLE, vol. 8, no. 13, 1 July 2009 (2009-07-01), pages 2014 - 2018, XP008161991 *
M. BAJ-KRZYWORZEKA ET AL.: "Tumor-derived microvesicles carry several surface determinants and mRNA of tumor cells and transfer some of these determinants to monocytes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 55, 2006, pages 808 - 818, XP019333260 *
M. SZAJNIK ET AL.: "Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T-cells (Treg)", PLOS ONE, vol. 5, no. 7, July 2010 (2010-07-01), pages 1 - 13, XP002697141 *
M. WYSOCZYNSKI ET AL.: "Lung cancer secreted microvesicles: Underappreciated modulators of microenvironment in expanding tumors", INTERNATIONAL JOURNAL OF CANCER, vol. 125, no. 7, 1 October 2009 (2009-10-01), pages 1595 - 1603, XP002592725 *
R. VALENTI ET AL.: "Tumor-released microvesicles as vehicles of immunosuppression", CANCER RESEARCH, vol. 67, no. 7, 1 April 2007 (2007-04-01), pages 2912 - 2915, XP002523308 *
X. LI ET AL.: "Nanovesicular vaccines: exosomes", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMANTALIS, vol. 53, no. 4, 2005, pages 329 - 335, XP009149577 *

Also Published As

Publication number Publication date
JP2013543519A (ja) 2013-12-05
WO2012165815A2 (ko) 2012-12-06
CN103221034A (zh) 2013-07-24
EP2617413A4 (en) 2014-03-19
US9220763B2 (en) 2015-12-29
EP2617413A2 (en) 2013-07-24
US20130177595A1 (en) 2013-07-11
KR20120132183A (ko) 2012-12-05

Similar Documents

Publication Publication Date Title
WO2012165815A3 (ko) 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
MX362550B (es) Inhibidores ciclicos de glutaminasa.
WO2012159754A3 (en) Individualized vaccines for cancer
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
WO2013068563A3 (en) Antibody molecules having specificity for human ox40
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
WO2013006547A3 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX2013009362A (es) Anticuerpo contra el csf-1r.
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2012083969A3 (en) Microrna for diagnosis of pancreatic cancer
IN2014DN06164A (ko)
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
WO2013034979A3 (en) Crystalline forms of cabazitaxel
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
HK1218860A1 (zh) 卵巢癌疫苗及接种方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12793342

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13823315

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012793342

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013534840

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE